Pulmonary embolism - Pipeline Insight, 2022

Pulmonary embolism - Pipeline Insight, 2022

DelveInsight’s, “Pulmonary embolism - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Pulmonary embolism Understanding

Pulmonary embolism: Overview

Pulmonary embolism (PE) occurs when there is a disruption to the flow of blood in the pulmonary artery or its branches by a thrombus that originated somewhere else. In deep vein thrombosis (DVT), a thrombus develops within the deep veins, most commonly in the lower extremities. PE usually occurs when a part of this thrombus breaks off and enters the pulmonary circulation. Very rarely, PE can occur from the embolization of other materials into the pulmonary circulation such as air, fat, or tumor cells. The spectrum of PE and DVT combined is referred to as venous thromboembolism.

""Pulmonary embolism - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary embolism pipeline landscape is provided which includes the disease overview and Pulmonary embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
 
Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Pulmonary embolism R&D. The therapies under development are focused on novel approaches to treat/improve in Pulmonary embolism.

This segment of the Pulmonary embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary embolism Emerging Drugs

Recombinant staphylokinase: Supergene

Recombinant staphylokinase contains Forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.

Further product details are provided in the report……..

Pulmonary embolism: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary embolism drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pulmonary embolism

There are approx. 5+ key companies which are developing the therapies for Pulmonary embolism. The companies which have their Pulmonary embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Pulmonary embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary embolism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pulmonary embolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary embolism drugs.

Pulmonary embolism Report Insights

Pulmonary embolism Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Pulmonary embolism Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs
 
Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Pulmonary embolism drugs?

How many Pulmonary embolism drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary embolism?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pulmonary embolism?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Pulmonary embolism and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Translational Sciences

Supergene

Angde Biotech Pharmaceutical

Yuhan

Key Products

TS 23

Recombinant staphylokinase: Supergene

Reteplase

YHP 1906